Ebola treatment

Submitted by [email protected] on Wed, 10/14/2020 - 12:00 PM

On October 14, 2020 the U.S. Food and Drug Administration (FDA) approved Inmazeb an antibody mixture consisting of atoltivimab, maftivimab, and odesivimab-ebgn. This is the FDA's first approved treatment for the Ebola virus. 

Content Source: Press Release

Content Author: US Food and Drug Administration

Submitted by [email protected] on Thu, 08/06/2020 - 12:00 PM

A recent study developed an in-facility mortality risk score that reflects Ebola Disease clinical severity and can assist in the clinical prioritization of Ebola patients. The study used the anonymized medical records of 1,077 laboratory-confirmed pediatric and adult EVD patients who received treatment at the 34 Military Hospital and Police Training School Ebola Treatment Centers in Sierra Leone between the period of June 2014 to April 2015.

Content Source: Science Direct

Content Author: Jia Bainga Kangbai, ChristianHeumann, MichaelHoelscher, FodaySahr, GuenterFroeschl

Submitted by nbertini on Wed, 08/14/2019 - 12:00 PM

This article acknowledges the importance of recent Ebola therapeutics and vaccine breakthroughs but also highlights the importance of infection control, community engagement, and disease surveillance as deciding factors in combating the Ebola crisis in the Democratic Republic of Congo.

Content Source: STAT

Content Author: Helen Branswell

Submitted by [email protected] on Mon, 08/12/2019 - 12:00 PM

Two treatments for Ebola which were undergoing trials in the Democratic Republic of Congo have been stopped early due to their success in treating Ebola. The two treatments will now be made widely available. One of the drugs is REGN-EB3, a cocktail of three monoclonal antibodies developed by Regeneron Pharmaceuticals. The other drug is mAb114, which is now being developed with Ridgeback Biotherapeutics. 

Content Source: AAAS Science Magazine

Content Author: Kai Kupferschmidt

Submitted by [email protected] on Thu, 03/28/2019 - 12:00 PM

The US Army Medical Research Institute of Infectious Diseases (USAMRIID) announced that, for the first time, the US Food and Drug Administration (FDA) has provided formal regulatory agreement for use of an animal model to support development of a drug candidate, remdesivir, for treating deadly Ebola virus infections.

Content Source: US Army Medical Research Institute of Infectious Diseases (USAMRIID)

Content Author: unknown

Submitted by [email protected] on Tue, 02/12/2019 - 12:00 PM

Doctors Without Borders/Médecins Sans Frontières (MSF) will participate in an ongoing randomized controlled trial of four potential Ebola treatments in North Kivu, Democratic Republic of Congo, in collaboration with the Ministry of Health, the international medical humanitarian organization said Tuesday.

Content Source: Médecins Sans Frontières (MSF)

Content Author: unknown

Submitted by [email protected] on Mon, 02/04/2019 - 12:00 PM

Historically, 60–70 percent of patients infected with Ebola virus in central African countries have died.

Content Source: Lancet

Content Author: François Lamontagne, Christophe Clément, Richard Kojan

Submitted by [email protected] on Thu, 01/24/2019 - 12:00 PM

mAb114 was well tolerated, showed linear pharmacokinetics, and was easily and rapidly infused, making it an attractive and deployable option for treatment in outbreak settings.

Content Source: Lancet

Content Author: Martin R Gaudinski, Emily E Coates, Laura Novik

Submitted by [email protected] on Mon, 01/14/2019 - 12:00 PM

In Congo, more than 600 people have contracted the Ebola virus which has claimed close to 400 lives.

Content Source: Voice of America

Content Author: Carol Pearson

Submitted by [email protected] on Wed, 01/09/2019 - 12:00 PM

The team of scientists demonstrated that a two-antibody cocktail called MBP134 could fully protect nonhuman primates and ferrets against lethal Ebola virus infections of caused by the Bundibugyo and Sudan strain as well as the deadliest Zaire strain.

Content Source: University of Texas Medical Branch at Galveston

Content Author: unknown